Arcturus Therapeutics

Arcturus Therapeutics News & Events

Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA–based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)

December 6, 2016

San Diego, Calif., Dec 6, 2016 – Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, announced today that it entered into collaboration with Takeda Pharmaceutical Company Limited, to develop RNA- based therapeutics for the treatment of NASH and other gastrointestinal (GI) related disorders, utilizing Arcturus’ wholly-owned therapeutic delivery platform LUNARTM and […]

Big Pharma Goes Small With Moves Into Incubator Space

October 4, 2016

By Scott Westcott, Contributing Writer From the limited view in his cramped cubicle at a Big Pharma company a few years back, Joseph Payne envisioned launching a startup to develop innovative ribonucleic acid (RNA) pharmaceuticals and technologies. Payne was confident he and a coworker had promising ideas, the necessary entrepreneurial mindset, and solid science to […]

Arcturus Therapeutics to Report Identification of LUNAR-HBV, a Potent Combination of Three UNA Oligomers Targeting All Hepatitis B Virus Genotypes at the AASLD Liver Meeting® 2016

October 3, 2016

Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, announced today that preclinical data for a multi-siRNA treatment of Chronic Hepatitis B Virus (HBV), developed in collaboration with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, will be presented in a poster at The Liver Meeting, the […]

Arcturus Therapeutics To Present At 2016 BIO International Convention in San Francisco

June 1, 2016

San Diego, Calif., June 1, 2016 – Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, announced today that its President & CEO, Joseph E. Payne, has been invited to present during the “Delivery: The Next Frontier of Biotherapeutics” session at the 2016 BIO International Convention in San Francisco on Tuesday, June […]

Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology

March 16, 2016

San Diego, Calif., March 16th, 2016 – Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, announced today that the European Patent Office (EPO) has issued a notice of its intent to grant the Company’s fundamental UNA Oligomer™ technology (EP Application No. 08780679.0), titled “Oligomers for Therapeutics.” “We are delighted with the […]

Arcturus Therapeutics Selected to Present at Biotech Showcase™ 2016

January 6, 2016

San Diego, Calif., January 6th, 2016 – Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, is pleased to announce that the Company has been selected to deliver a corporate presentation at the 8th annual Biotech Showcase™ conference being held January 11-13, 2016 during the JP Morgan Healthcare Conference in San Francisco, […]